Pioneered by anti–tumor necrosis factor (TNF) antibodies (Abs), the introduction of targeted therapies against inflammatory cytokines transformed the clinical outcome of patients with major chronic immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD) (1–3). Here, TNF is linked to rheumatoid arthritis.